Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer

The purpose of this study is to assess the safety, the maximum tolerated dose and the recommended dose for phase II studies of a chemotherapy-combination of sorafenib, irinotecan, and 5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) as first-line treatment for metastatic colorectal cancer.

本研究旨在评估索拉非尼（sorafenib）、伊立替康（irinotecan）与5-氟尿嘧啶（5-fluorouracil，5-FU）/亚叶酸（folinic acid，FA）组成的FOLFIRI联合化疗方案，作为转移性结直肠癌一线治疗方案时的安全性、最大耐受剂量及Ⅱ期临床试验推荐剂量。